• AndersenNynne NyboeNNNynne Nyboe Andersen, Tine Jess, Department of Epidemiology Research, Statens Serum Institut, DK-2300 Copenhagen, Denmark. and Tine Jess.
• Nynne Nyboe Andersen, Tine Jess, Department of Epidemiology Research, Statens Serum Institut, DK-2300 Copenhagen, Denmark.
• World J. Gastroenterol. 2014 Nov 21; 20 (43): 16014-9.

AbstractTumor necrosis factor-α (TNF-α) inhibitors are biological agents introduced in the late 1990s for the treatment of different immune-mediated diseases as inflammatory bowel disease, rheumatoid arthritis and psoriasis. The most commonly used TNF-α antagonists are infliximab, adalimumab, and certolizumab pegol, and though highly effective in lowering inflammation, the efficacy must be weighed against the potential for adverse events. The treatment-induced immunosuppression is suspected to increase the risk of infections, including the risk of reactivation of latent tuberculosis, as the TNF-α cytokine plays an important role in the immune function. In this topic highlight a short overview of the infection risk associated with TNF-α inhibiter therapy is outlined with a focus on the overall risk of serious infections, mycobacterial infection and latent viral infections.

34 keywords...

hide…